...
机译:BCL2抑制剂venetoclax上CLL进展的临床病理特征和结果
Royal Melbourne Hosp Dept Clin Haematol &
Bone Marrow Transplantat Parkville Vic Australia;
Univ Melbourne Fac Med Dent &
Hlth Sci Parkville Vic Australia;
Walter &
Eliza Hall Inst Med Res Div Canc &
Haematol 1G Royal Parade Parkville Vic 3052;
Victorian Comprehens Canc Ctr Parkville Vic Australia;
Royal Melbourne Hosp Dept Clin Haematol &
Bone Marrow Transplantat Parkville Vic Australia;
Victorian Comprehens Canc Ctr Parkville Vic Australia;
Univ Melbourne Fac Med Dent &
Hlth Sci Parkville Vic Australia;
Victorian Comprehens Canc Ctr Parkville Vic Australia;
Royal Melbourne Hosp Melbourne Epicentre Parkville Vic Australia;
Walter &
Eliza Hall Inst Med Res Div Canc &
Haematol 1G Royal Parade Parkville Vic 3052;
Univ Melbourne Fac Med Dent &
Hlth Sci Parkville Vic Australia;
Royal Melbourne Hosp Dept Clin Haematol &
Bone Marrow Transplantat Parkville Vic Australia;
机译:BCL2抑制剂venetoclax上CLL进展的临床病理特征和结果
机译:BCL2选择性抑制剂Venetoclax通过不依赖TP53的机制诱导患者CLL细胞快速发作凋亡
机译:P1.03-006具有ALK重新排列的抗鳞状细胞肺癌的临床病理特征和良差的抗碱性抑制剂
机译:通过高阶多模式多任务特征学习预测认知结果的进展
机译:来自不同组织部位的CLL细胞的基因表达谱:鉴定涉及存活,增殖和进展的基因
机译:BCL2选择性抑制剂Venetoclax通过不依赖TP53的机制诱导患者CLL细胞的快速发作凋亡
机译:BCL2选择性抑制剂venetoclax通过TP53独立机制诱导患者CLL细胞的快速发作凋亡